Law Offices of Thomas J. Lamb

  • Asbestos & Mesothelioma
  • Benzene Diseases
  • Camp Lejeune Cases
  • Drug Injury
  • Free Case Evaluation
  • About Us

August Update: Possible Link Between Hepatitis C Drugs & Liver Cancer

September 1, 2017 By Law Offices of Thomas J. Lamb, P.A.


In the past several years, there has been much controversy surrounding the possible link between a class of Hepatitis C drugs known as direct-acting antivirals (DAAs) and hepatocellular carcinoma (HCC), or liver cancer.  The DAA drugs include Harvoni, Sovaldi, Viekira Pak, Technivie, Olysio, Daklinza, Epclusa, and Zepatier.

In July, I wrote an article on a study that was posted in the July 2017 edition of Gastroenterology that weighed in on this controversy.  This study provided additional evidence that DAA treatment does not entail a higher risk of liver cancer.

Although the articles that have been published on the potential link between DAAs and liver cancer tend to conflict with one another concerning whether a definite causal relationship occurs between the two, there are some points of agreement.  A recent Medscape article discusses these commonalities in detail, and is the source for the information below.

Firstly, advanced liver disease carries the strongest risk for liver cancer development.  One study found that in addition to advanced liver disease, treatment failure was also associated with HCC.

Another study pointed out that patients treated with DAAs are more likely than untreated HCV patients to have conditions that independently increase their risk of liver cancer.  Rather than the DAAs themselves, these conditions–such as older age, cirrhosis, and portal hypertension–may be to blame if a patient treated with DAAs experiences an occurrence or recurrence of HCC.

Moreover, additional research suggests that patients who develop HCC after DAA therapy may have had unidentified tumors present before DAA treatment ever occurred.  However, some research proposed a theory that DAAs may reduce the immune system’s ability to target certain tumors, which may be responsible for their formation in patients with cirrhosis.

Secondly, many studies show a decreased rate of newly-occurring liver cancer in patients with HCV cirrhosis after sustained virologic response (SVR) due to DAA treatment.  See my previous article for a list of some of these studies.

Thirdly, patients with active liver cancer show lower rates of SVR, which means that they are less likely to have the Hepatitis C virus absent from their blood for more than 12 weeks.

Until a definitive causal link between DAAs and liver cancer is–or is not–drawn, we will continue to monitor the medical literature for more information, and report on significant developments.

 

 

Written by: Heather Helmendach, Legal Assistant
Law Offices of Thomas J. Lamb, P.A.


Drug Injury Watch
: Side Effects News & Reports

Drug Injury Law: Medical & Legal Information

Filed Under: Unsafe Drugs Tagged With: daa drugs, Daklinza, direct-acting antivirals, drugs side effects, Epclusa, Harvoni, hcc, hepatitis c drugs, hepatocellular carcinoma, Liver Cancer, liver cancer causes, Olysio, Sovaldi, Technivie, Viekira Pak, Zepatier

Find What You Want Here

Get Free Case Evaluation

We encourage you to submit an online Case Evaluation Form – it is confidential and there is no obligation.

Or call our toll-free number, 800-426-9535, to speak directly to attorney Tom Lamb about your possible case.

Feel Free To Contact Us

Quick Contact Form
 
Send an Email to Tom Lamb

(800) 426-9535

Main Navigation Menu

  • About Our Firm
  • Asbestos-Mesothelioma Cases
  • Benzene Disease Claims
  • PFAS Firefighter Gear Lawsuits
  • Camp Lejeune Cases
  • GenX Water Cancer Cases
  • Drug Injury Lawsuits
  • Breast Implant Cancer Cases
  • Philips Breathing Devices Cases
  • Case Evaluation Menu
  • Quick Contact Form
  • Frequently Asked Questions
  • Medical Records Charges
  • Collection of Articles
  • Sitemap

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Websites

Drug Injury Law
Drug Injury Watch
Drug Safety Developments
Asbestos & Mesothelioma

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Frequently Asked Questions
  • Disclaimer and Copyright Notices

Copyright © 2023 · Law Offices of Thomas J. Lamb, P.A.